Encouraging data for ViiV’s long-acting, two-drug HIV therapy
ViiV Healthcare has unveiled encouraging mid-stage data backing a long-acting formulation of its two-drug regimen cabotegravir and rilpivirine for the treatment of HIV.
According to long-term data from the Phase II LATTE-2 trial, the injectable regimen - administered either every eight weeks or every four weeks - showed “high rates of virologic response, long-term durability of virologic response and good overall tolerability,” the firm noted.
At 160 weeks, 90% and 83% of the patients receiving the injectable cabotegravir/rilpivirine every eight and four weeks, respectively, remained virally suppressed.
Read more: http://www.pharmatimes.com/news/encouraging_data_for_viivs_long-acting,_two-drug_hiv_therapy_1257551
According to long-term data from the Phase II LATTE-2 trial, the injectable regimen - administered either every eight weeks or every four weeks - showed “high rates of virologic response, long-term durability of virologic response and good overall tolerability,” the firm noted.
At 160 weeks, 90% and 83% of the patients receiving the injectable cabotegravir/rilpivirine every eight and four weeks, respectively, remained virally suppressed.
Read more: http://www.pharmatimes.com/news/encouraging_data_for_viivs_long-acting,_two-drug_hiv_therapy_1257551